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Abstract
Background: Clinically proven over-the-counter (OTC) treatment options are becoming increasingly important in
the self-management of acute sore throat. The aim of this study was to determine the analgesic and sensorial
benefits of two different amylmetacresol/2,4-dichlorobenzyl alcohol (AMC/DCBA) throat lozenge formulation
variants, AMC/DCBA Warm lozenge and AMC/DCBA Cool lozenge, compared with an unflavoured, non-medicated
placebo lozenge in the relief of acute sore throat due to upper respiratory tract infections.
Methods: In this multicentre, randomised, double-blind, single-dose study, 225 adult patients with acute sore
throat were randomly assigned to receive either one AMC/DCBA Warm lozenge (n = 77), one AMC/DCBA Cool
lozenge (n = 74) or one unflavoured, non-medicated lozenge (matched for size, shape and demulcency; n = 74).
After baseline assessments, patients received their assigned lozenge and completed four rating assessments at 11
timepoints from 1 to 120 minutes post dose. Analgesic properties were assessed by comparing severity of throat
soreness and sore throat relief ratings. Difficulty in swallowing, throat numbness, functional, sensorial and
emotional benefits were also assessed.
Results: Both the AMC/DCBA Warm and AMC/DCBA Cool lozenge induced significant analgesic, functional,
sensorial and emotional effects compared with the unflavoured, non-medicated lozenge. Sore throat relief,
improvements in throat soreness and difficulty in swallowing, and throat numbness were observed as early as 1-5
minutes, and lasted up to 2 hours post dose. Sensorial benefits of warming and cooling associated with the AMC/
DCBA Warm and AMC/DCBA Cool lozenge, respectively, were experienced soon after first dose, and in the case of
the latter, it lasted long after the lozenge had dissolved. Emotional benefits of feeling better, happier, less
distracted and less frustrated were reported in those taking either of the AMC/DCBA throat lozenge variants, with
no differences in adverse events compared with the unflavoured, non-medicated lozenge.
Conclusions: AMC/DCBA Warm and AMC/DCBA Cool lozenges are well-tolerated and effective OTC treatment
options, offering functional, sensorial and emotional benefits to patients with acute sore throat, over and above
that of the rapid efficacy effects provided.
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Acute sore throat is an inflammatory condition charac-
terised by pain, redness, heat and swelling. Inflammatory
mediators, such as bradykinin and prostaglandins,
released following local responses to cell damage are
known to cause some of the sore throat symptoms,
including pain and irritation [1]. Pro-inflammatory cyto-
kines have also been linked to ‘sickness’ behaviour,
which in turn is associated with increased pain sensitiv-
ity in cases of microbial infection [2]. Moreover, sore
throat and ‘sickness’ a r eh i g h l yc o r r e l a t e d ,w h e r ea
greater level of pain experienced by the patient is asso-
ciated with a greater feeling of sickness/unwellness [3],
often resulting in remedial action being sought.
Up to 80% of sore throats are caused by viruses and
not bacteria [4,5]. Therefore, antibiotics are ineffective
in the majority of cases and are not recommended for
the primary treatment of acute sore throat by several
clinical bodies in the EU [6,7]. Clinically proven over-
the-counter (OTC) options that are rapid-acting, safe
and effective in providing symptomatic relief to acute
sore throat are becoming increasingly important in the
self-management of this condition. Amylmetacresol/2,4-
dichlorobenzyl alcohol (AMC/DCBA) throat lozenges
(more commonly known as Strepsils
® lozenges; Reckitt
Benckiser Healthcare International, UK) are a range of
medicated throat lozenges available OTC in the UK and
many other countries for the symptomatic relief of
mouth and throat infections, and acute sore throat. All
AMC/DCBA throat lozenges contain the two core active
ingredients, AMC (0.6 mg) and DCBA (1.2 mg), both of
which possess antibacterial [8,9], antiviral [10] and local
anaesthetic [11] properties. Furthermore, clinical evi-
dence available supports the efficacy and safety of
AMC/DCBA throat lozenges in the rapid relief of acute
sore throat due to upper respiratory tract infections
(URTIs) [12-15]. It should be noted that although such
OTC products are used to provide symptomatic relief of
viral and bacterial pharyngitis, worsening of symptoms
m a ys u g g e s tam o r es e r i o u sc a u s ea n dt h eo p i n i o no fa
medical professional should be sought. Data suggest that
the analgesic and functional benefits observed with
AMC/DCBA throat lozenges were attributable to the
active ingredients, AMC and DCBA, as these benefits
were significantly over and above the demulcent proper-
ties of non-medicated lozenges [15]. AMC/DCBA Cool
lozenge is a formulation variant of AMC/DCBA throat
lozenge that has been associated with sensorial effects
such as cooling, coating and soothing in healthy volun-
teers [16]. However, up until now neither the efficacy
nor the sensorial benefits of this lozenge formulation
have been investigated in patients with acute sore
throat, hence the basis of part of this study.
In a more recent monadic, in-home, consumer
research study conducted by Reckitt Benckiser Health-
care International that adopted the same methodology
as Shephard et al. [16], approximately 86% of partici-
pants said they like to feel ‘warm’ and comforted when
they are suffering from a sore throat (Personal Com-
munications). When these healthy adult volunteers
were randomly allocated to one of two lozenges, either
a new AMC/DCBA throat lozenge variant (known as
AMC/DCBA Warm lozenge) or a control lozenge,
more participants taking the AMC/DCBA Warm
lozenge (89%) said they felt a warming sensation than
those who took the control lozenge (9%; p = 0.01).
Sixty-five percent of participants felt it within 30 sec-
onds and 85% felt the effects began in the first minute.
More participants taking the AMC/DCBA Warm
lozenge (58%) agreed that the experience provided by
the Warm lozenge was ‘comforting’ compared with
23% in the control lozenge group (p < 0.0001). This
consumer research study demonstrated that the AMC/
DCBA Warm lozenge provided sensorial effects in
healthy volunteers, but it is not known whether these
effects would be seen in patients with acute sore
throat, and what other benefits the product could deli-
ver in this patient population.
This multicentre, randomised, double-blind, single-
dose study was designed to examine the analgesic prop-
erties of the two AMC/DCBA throat lozenge variants
(AMC/DCBA Warm and AMC/DCBA Cool lozenges)
compared with an unflavoured, non-medicated placebo
lozenge (referred to herein as unflavoured, non-
medicated lozenge) in patients with acute sore throat
over a period of 2 hours. In addition, sensorial
and emotional benefits were investigated via a patient
questionnaire survey.
Methods
Participants
This study was approved by Fife & Forth Valley
Research Ethics Committee. Between 12 January and 20
February 2009, 225 patients with acute sore throat due
to URTI who attended a GP referral practice or
attended CPS Research in the UK directly in response
to advertising were enrolled into the study. Eligible
patients were male or female adults aged between 16
and 75, with a confirmed diagnosis of acute sore throat
due to URTI and an onset within the previous 4 days.
All patients gave written informed consent and had a
sore throat score of ≥6 on the Throat Soreness Scale at
baseline and the presence of tonsillopharyngitis, as con-
firmed by the study physicians recording a score of ≥3
points on the expanded 21-point Tonsillopharyngitis
Assessment (TPA).
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Patients were randomised to receive either one of two
AMC/DCBA throat lozenge variants or an unflavoured,
non-medicated lozenge (placebo):
i. AMC/DCBA Cool lozenge, containing the active
ingredients AMC (0.6 mg) and DCBA (1.2 mg),
and various excipients including specially formu-
lated ‘cooling flavours’; also known as Strepsils
®
Cool lozenge; Reckitt Benckiser Healthcare
International
ii. AMC/DCBA Warm lozenge, containing the active
ingredients AMC (0.6 mg) and DCBA (1.2 mg), and
various excipients including specially formulated
‘warming flavours’; Reckitt Benckiser Healthcare
International
iii. Unflavoured, non-medicated lozenge (sugar-based
non-medicated placebo lozenge; size, shape and
demulcency matched with the two AMC/DCBA
throat lozenge variants)
Note that the placebo lozenge was unflavoured, while
the active lozenges were flavoured. The marked differ-
ence in flavour between the two active lozenges and the
flavour associated with the active ingredients themselves
made it impossible to introduce a control specific for
this variable.
Objectives
The primary objective of this study was to determine
the analgesic properties of two new formulation var-
iants of AMC/DCBA throat lozenges (AMC/DCBA
Cool and AMC/DCBA Warm lozenges) in patients
with acute sore throat compared with an unflavoured,
non-medicated lozenge.
In addition to the analgesic endpoints, functional mea-
sures of difficulty in swallowing and throat numbness
were also assessed. Secondary objectives of this study
were to determine functional impairment scores, emo-
tional and sensorial benefits of the lozenges via
responses to a consumer questionnaire.
Primary and secondary outcome measures
The primary efficacy endpoint for this study was area
under the change-from-baseline curve (AUC) in severity
of throat soreness from 0 to 2 hours. The secondary
efficacy endpoints were:
￿ Change from baseline in severity of throat soreness
(using the 11-point Throat Soreness Scale); sore
throat relief (using a 7-point scale); change from
baseline in difficulty in swallowing (using a 100 mm
visual analogue scale [VAS] from ‘not difficult’ to
‘very difficult’ to swallow); and throat numbness
(using a 5-point categorical scale), all measured at 1,
5, 10, 15, 30, 45, 60, 75, 90, 105 and 120 minutes
post dose
￿ Total sum of pain relief ratings (TOTPAR): AUC
from baseline to 2 hours post first dosing for sore
throat relief
￿ AUC from baseline to 2 hours for the change from
baseline in difficulty swallowing (using a 100 mm
visual analogue scale [VAS] from ‘not difficult’ to
‘very difficult’ to swallow)
￿ AUC for throat numbness (using a 5-point scale)
measurements from 1 to 120 minutes
￿ Responses to consumer questionnaire relating to
functional impairment and to patients’ opinions
about the type of pain relief provided; sensorial ben-
efits experienced (i.e. warming and cooling sensa-
tions); the speed and duration of effects experienced;
emotional benefits, i.e. if they felt any better, any
happier, any less frustrated, or any less distracted
than before taking a lozenge; and overall treatment
rating at 2 hours
Sample size determination
Sample size determination was based on a previous
study with AMC/DCBA throat lozenges conducted at
the same research centre [14]. The difference in the
m e a nA U Cf o rt h ec h a n g ef r o mb a s e l i n ei nt h es e v e r i t y
of throat soreness from 0 to 2 hours between the AMC/
DCBA throat lozenges and unflavoured, non-medicated
lozenges for patients with a TPA ≥3 was assumed to be
of similar magnitude and therefore 75 patients per
group would be sufficient to provide 90% power to
detect a difference of 0.58 in the mean AUC (75% of the
effect observed in the previous study) between either of
the two test lozenges and the unflavoured, non-medi-
cated lozenge using a 2-tailed two sample t- t e s ta tt h e
5% significance level.
Randomisation and blinding
The method of randomisation used for the assignment
of patients to treatment groups was similar to that
described previously by McNally et al.[ 1 5 ] .At h i r d -
party blinding method was employed, where each
patient was blindfolded and provided with a single
lozenge (from an opaque blister pack) in the clinic by
an independent member of the investigational staff who
was not involved in the study assessments. Patients were
advised that they might experience a cool or warm sen-
sation. Once the lozenge was put into the mouth, the
blindfold was removed. Patients were instructed to suck
the lozenge slowly, moving the lozenge around the
mouth, until it had dissolved, without chewing or
crunching the lozenge.
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At the screening visit, a medical history, current medi-
cal use, therapy history in the past 14 days, baseline
TPA and the patient’s current medical status were
confirmed and recorded by the investigator. At the
pre-dosing stage and under supervision of the study
nurse or investigator, patients recorded throat soreness
and difficulty in swallowing scores. Post dose, patients
recorded throat soreness, difficulty in swallowing,
throat numbness and sore throat relief scores at 1, 5,
10, 15, 30, 45, 60, 75, 90, 105 and 120 minutes. In
addition, patients completed the patient questionnaire
pre-dose, and at time intervals of 1, 5, 20, 60 and 120
minutes post dose. All adverse events reported sponta-
n e o u s l yb yt h ep a t i e n to ri nr e s p o n s et oq u e s t i o n i n go r
observation by the investigat o ra n d / o rt h es t u d yn u r s e
pre-dose, 2 hours post dose and at the follow-up visit
(1-3 days post dose) were recorded in the patient’s
case report form.
Statistical analyses
All statistical tests performed were 2-tailed with signifi-
cance determined by reference to the 5% significance
level, unless otherwise stated. The null hypothesis at all
times was the equality of each of the test lozenges being
compared with an unflavoured, non-medicated lozenge.
Comparisons between each of the test lozenges and
unflavoured, non-medicated lozenge were reported with
95% confidence intervals (CIs) for the difference. The
primary efficacy endpoint was analysed by analysis of
covariance (ANCOVA) with baseline throat soreness
severity as a covariate and factors for treatment group
and referral centre. Treatment group differences were
estimated using the mean square error from the
ANCOVA and using Fisher’s protected Least Square
Difference method.
All secondary endpoints and the supportive analyses
were considered as descriptive evidence of efficacy and
were analysed without any procedures to account for
multiple comparisons. Pair-wise differences between
treatment groups in the proportion of patients reporting
treatment-emergent adverse events were compared via
chi-square tests. Questions with binary responses were
analysed using a logistic regression model with factors
for treatment group and centre and a covariate for base-
line throat soreness severity.
Questions on non-numeric ordinal scales were ana-
lysed using a proportional odds model using PROC
LOGISTIC in SAS with factors for treatment group and
centre group and a covariate for baseline throat soreness
severity. Questions on numeric ordinal scales were ana-
l y s e du s i n gt h es a m eA N C O V Am o d e la st h ep r i m a r y
efficacy endpoint, or by ANCOVA with factors for treat-
ment group and centre and covariates for the baseline
throat soreness and the relevant baseline score for the
specific question.
Results
Participant flow and baseline demographics
A total of 225 patients were enrolled into the study and
randomised to receive one of three study lozenges
(Figure 1). No patients withdrew from the study. The
intention-to-treat (ITT) and safety analyses sets were
identical and consisted of all 225 patients randomised.
Twenty-two patients (two from the AMC/DCBA Warm
lozenge group, 10 from the AMC/DCBA Cool lozenge
group and 10 from the unflavoured, non-medicated
lozenge group) were excluded from the per-protocol
(PP) analysis set, which therefore consisted of 203
patients, mostly owing to baseline throat soreness being
too low (Figure 1). The only variables assessed with the
PP analysis set were the primary efficacy endpoint and
TOTPAR. Baseline demographics data show that the
patients enrolled were predominantly Caucasian with
slightly more women than men; the overall mean age
was 31.7 years, and the mean duration of sore throat
was 2.2 days. All of these parameters were well balanced
between each of the treatment groups (Table 1).
Primary efficacy endpoint
AUC from baseline to 2 hours in severity of throat soreness
The AMC/DCBA Warm lozenge produced significantly
different AUC results for the change from baseline to
2 hours in severity of throat soreness compared with the
unflavoured, non-medicated lozenge (p = 0.001; Table 2).
Similarly, the AMC/DCBA Cool lozenge also significantly
reduced the severity of throat soreness versus the unfla-
voured, non-medicated lozenge, as measured by AUC for
the change from baseline to 2 hours (p < 0.0001). In the
ITT analysis, the terms for treatment and baseline throat
soreness were both statistically significant (p < 0.0001),
whereas the term for centre was not (p = 0.84). Statistical
conclusions from the PP analysis were qualitatively
identical to those obtained with the ITT analysis (Table 2).
Secondary endpoints
Effect on severity of throat soreness
Both AMC/DCBA Warm and AMC/DCBA Cool
lozenges produced significant changes from baseline in
throat soreness between 5 and 120 minutes and 1 and
120 minutes post dose, respectively, compared with the
unflavoured, non-medicated lozenge (all p < 0.05, all p <
0.01, respectively; Figure 2).
Effect on sore throat relief
AMC/DCBA Warm lozenges induced significant sore
throat relief compared with the unflavoured, non-medicated
lozenge at each assessment timepoint between 5 and
120 minutes (all p < 0.01) and AMC/DCBA Cool lozenges
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post dose (all p < 0.001; Figure 3). In addition, both AMC/
DCBA throat lozenge variants provided significantly differ-
ent TOTPAR compared with the unflavoured, non-medi-
cated lozenge (p = 0.0001 and p < 0.0001, respectively;
Table 3A).
Effect on difficulty in swallowing
The AUC for change from baseline to 2 hours post dose in
difficulty in swallowing showed significant differences with
both AMC/DCBA throat lozenge variants compared with
the unflavoured, non-medicated lozenge (Table 3B). At 1
minute post dose, the AMC/DCBA Cool lozenge induced
significantly different changes from baseline in difficulty in
swallowing compared with the unflavoured, non-medi-
cated lozenge (p < 0.0001). A significant improvement in
swallowing remained at each of the subsequent assessment
timepoints between 5 and 120 minutes (all p < 0.01). The
AMC/DCBA Warm lozenge induced significantly different
changes from baseline in difficulty in swallowing com-
pared with the unflavoured, non-medicated lozenge at
each of the timepoints between 5 and 60 minutes and at
90 minutes post dose (all p < 0.05; Figure 4).
PATIENTS SCREENED
n=225
PATIENTS RANDOMISED
n=225
AMC/DCBA
WARM LOZENGE
n=77
UNFLAVOURED,
NON-MEDICATED 
LOZENGE
n=74
AMC/DCBA
COOL LOZENGE
n=74
COMPLETED
n=74
COMPLETED
n=74
COMPLETED
n=77
ANALYSED
Full analysis set (n=77)
Per-protocol set (n=75)
Throat soreness <6 (n=1)
Inadmissible timing of
ANALYSED
Full analysis set (n=74)
Per-protocol set (n=64)
Throat soreness <6 (n=8)
Missing assessment (n=2)
ANALYSED
Full analysis set (n=74)
Per-protocol set (n=64)
Throat soreness <6 (n=10)
Inadmissible timing of 
assessment (n=1)
Safety set
(n=77)
Missing assessment (n 2)
Safety set
(n=74)
Safety set
(n=74)
Figure 1 Patient flow for selection, randomisation and analysis.
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The AUC data for throat numbness measurements from 1
to 120 minutes post dose demonstrated significant differ-
ences between both AMC/DCBA throat lozenge variants
and the unflavoured, non-medicated lozenge (Table 3C).
Both AMC/DCBA Warm and AMC/DCBA Cool lozenges
induced significant throat numbness compared with the
unflavoured, non-medicated lozenge, an effect that peaked
at 15 minutes post dose for AMC/DCBA Warm lozenge
(p < 0.001) and 10 minutes post dose for AMC/DCBA
Cool lozenge (p < 0.001; Figure 5).
Effect on functional impairment scores
Both AMC/DCBA Warm and AMC/DCBA Cool lozenges
provided statistically significant improvements in swallow-
ing compared with the unflavoured, non-medicated
lozenge (p = 0.018 and p = 0.011, respectively; Table 4).
For talking and the overall score, only the AMC/DCBA
Warm lozenge achieved statistically significant reductions
versus the unflavoured, non-medicated lozenge (p = 0.003
and p = 0.03, respectively). No significant difference was
observed between either of the AMC/DCBA throat
lozenge variants and unflavoured, non-medicated lozenge
for concentrating and reading (Table 4).
Early effects - Sensorial effects experienced
At the first moment of lozenge consumption, signifi-
cantly more patients taking the AMC/DCBA Cool
lozenge than the unflavoured, non-medicated lozenge
reported experiencing soothing relief (31.1% vs 12.3% of
patients, respectively; p < 0.01) and said yes to the ques-
tion, ‘Did the throat lozenge provide cooling relief at
Table 1 Patient demographics - ITT set
Variable AMC/DCBA
Warm lozenge
AMC/DCBA
Cool lozenge
Unflavoured,
non-medicated
lozenge
Overall
Number of patients (n) 77 74 74 225
Age (year) (Mean ± SD) 30.3 ± 12.2 32.4 ± 14.7 32.6 ± 13.2 31.7 ± 13.3
Gender (% male) 41.6 39.2 41.9 40.9
Race (% Caucasian) 97.4 97.3 95.9 96.9
Alcohol drinker (%) 83.1 86.5 75.7 81.8
Current smoker (%) 36.4 37.8 35.1 36.4
Former smoker (%) 26.0 17.6 14.9 19.6
Duration of sore throat (days) (Mean ± SD) 2.3 ± 0.8 2.2 ± 0.7 2.0 ± 0.9 2.2 ± 0.8
Duration of URTI (days) (Mean ± SD) 3.0 ± 2.7 2.4 ± 1.0 3.6 ± 7.1 3.0 ± 4.4
SD, standard deviation; URTI, upper respiratory tract infection.
Table 2 AUC from baseline to 2 hours post-dose for the change from baseline in throat soreness
AMC/DCBA
Warm lozenge
AMC/DCBA
Cool lozenge
Unflavoured,
non-medicated
lozenge
ITT Set
N 77 74 74
Mean ± SD -1.83 ± 1.50 -2.07 ± 1.47 -1.00 ± 1.61
LS mean
a -1.78 -2.06 -0.98
Parameter estimates LS mean
b 95% CI P-value
AMC/DCBA Warm lozenge - unflavoured, nonmedicated lozenge -0.80 -1.27,-0.33 0.001**
AMC/DCBA Cool lozenge - unflavoured nonmedicated lozenge -1.08 -1.56,-0.60 <0.0001***
PP Set
N 75 64 64
Mean ± SD -1.87 ± 1.50 -2.16 ± 1.50 -1.25 ± 1.39
LS mean
a -1.83 -2.09 -1.11
Parameter estimates LS mean
b 95% CI P-value
AMC/DCBA Warm lozenge - unflavoured, nonmedicated lozenge -0.72 -1.21,-0.23 0.004**
AMC/DCBA Cool lozenge - unflavoured, nonmedicated lozenge -0.98 -1.48,-0.47 0.0002***
aEstimated from ANCOVA model with factors for treatment and centre and a covariate for baseline throat soreness.
bA negative difference favours the first treatment against second treatment.
**Significantly different compared with the unflavoured, non-medicated lozenge at the 1% level.
***Significantly different compared with the unflavoured, non-medicated lozenge at the 0.1% level.
CI, confidence interval; LS, least-squares; SD, standard deviation; ITT, intention-to-treat; PP, per-protocol.
Throat soreness measured on an 11-point scale where 0 = Not sore, 10 = Very sore.
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respectively; odds ratio [OR] 15.78 [95% confidence
interval (CI) 6.32, 39.42]; p < 0.0001). Similarly, signifi-
cantly more patients who took AMC/DCBA Warm
lozenge than those who took the unflavoured, non-
medicated lozenge said yes to the question, ‘Did the
throat lozenge provide warming relief at first moment of
lozenge consumption?’ (46.8% vs 13.7%, respectively; OR
5.62 [95% CI 2.50, 12.62]; p < 0.0001) - most commonly
described as comforting warming, or deeply warming or
gentle warming.
When asked at 1 minute, a cooling sensation was felt
significantly earlier with AMC/DCBA Cool lozenge than
with the unflavoured, non-medicated lozenge (OR 20.10
[95% CI 9.69, 41.69]; p < 0.0001), with 60.8% of patients
experiencing this within 5 seconds and 78.4% within
10 seconds. For AMC/DCBA Warm lozenge, a warming
sensation was felt significantly earlier than the unfla-
voured, non-medicated lozenge (OR 8.80 [95% CI 4.70,
16.49]; p < 0.0001) with 62.4% experiencing this within
30 seconds.
Effects at 2 hours - Duration of sensorial effects
experienced
When asked at 2 hours post dose, ‘How long did the
cooling sensation of the throat lozenge last in your
mouth?’, only the AMC/DCBA Cool lozenge produced a
cooling sensation in the throatt h a tl a s t e ds i g n i f i c a n t l y
longer than the unflavoured, non-medicated lozenge
(OR 0.11 [95% CI 0.06, 0.21]; p < 0.0001).
Similarly, when the same question was asked at
2 hours about the duration of warming sensation, only
the AMC/DCBA Warm lozenge produced a warming
s e n s a t i o ni nt h et h r o a tt h a tl a sted significantly longer
than the unflavoured, non-medicated lozenge (OR 0.16
[95% CI 0.09, 0.30]; p < 0.0001).
Emotional benefits
Significantly more patients who received one of the two
AMC/DCBA throat lozenge variants (51.9%, 57.5%, for
AMC/DCBA Warm and AMC/DCBA Cool lozenge,
respectively) said yes to the question, ‘At 2 hours post
dose, do you feel any better than before you took the
throat lozenge?’ compared with those who received the
Figure 2 Mean change from baseline in throat soreness from 1 to 120 minutes post dose - ITT set.
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0.0001).
In addition, significantly more patients who took either
one of the AMC/DCBA throat lozenge variants reported
feeling less distracted, less frustrated and happier than
before they took the throat lozenge at 2 hours post dose
compared with those who took an unflavoured, non-
medicated lozenge (p < 0.02 in all cases; Figure 6).
Overall ratings on throat lozenge as a treatment for sore
throat
Both AMC/DCBA throat lozenge variants yielded signif-
icantly higher scores than unflavoured, non-medicated
lozenge (p < 0.0001 in both cases) when the question,
‘How would you rate this throat lozenge as a treatment
for sore throat?’ was asked at 2 hours and recorded on
an 11-point scale where 0 = Poor and 10 = Excellent.
The least squares (LS) mean difference between the
AMC/DCBA Warm lozenge, AMC/DCBA Cool lozenge
and the unflavoured, non-medicated lozenge was 2.57
(95% CI 1.68, 3.45) and 3.00 (95% CI 2.11, 3.90), respec-
tively; both p < 0.0001.
Adverse events
Eighteen out of 225 patients (8%) reported a total of
23 treatment-emergent adverse events. The highest
number of events was reported by patients in the
unflavoured, non-medicated lozenge group with 10
patients reporting 11 treatment-emergent events, while
four patients in the AMC/DCBA Warm lozenge group
reported a total of eight events and four patients in
the AMC/DCBA Cool lozenge group reported one
event each. The majority of events (20 out of 23, i.e.
87%) were mild in severity, and none were considered
to be definitely, probably or possibly related to the
s t u d ym e d i c a t i o n .T h e r ew e r en ot r e a t m e n t - e m e r g e n t
serious adverse events.
Most adverse events were related to the patient’s URTI,
such as headache, cough and congestion, with headache
being the most common treatment-emergent adverse
event reported (i.e. seven reports by seven patients; three
from the unflavoured, non-medicated lozenge group and
two from each of the AMC/DCBA throat lozenge variant
groups). There were no statistically significant pair-wise
Figure 3 Mean sore throat relief from 1 to 120 minutes post-dose - ITT population.
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Page 8 of 14treatment differences between the treatment groups in
the proportion of patients reporting treatment-emergent
adverse events.
Discussion
The results obtained were robust with qualitatively
identical conclusions drawn from the equivalent PP
analyses where performed. In addition, there was no
evidence to suggest that the results differed signifi-
cantly between centres. A single dose of the AMC/
DCBA Warm lozenge and the AMC/DCBA Cool
lozenge exhibited significant analgesic, functional and
emotional benefits compared with the unflavoured,
non-medicated lozenge, and also demonstrated a num-
ber of sensorial effects. With the AMC/DCBA Warm
lozenge, sore throat relief and improvements in throat
soreness and difficulty in swallowing were observed as
early as 5 minutes post dose, and lasted for up to
2 hours. Similarly, the AMC/DCBA Cool lozenge pro-
vided sore throat relief and improvements in throat
soreness and difficulty in swallowing, but at the earlier
timepoint of 1 minute post dose, which also lasted
long after the lozenge had dissolved, for up to 2 hours
post dose. The mean time (± standard deviation) for a
AMC/DCBA throat lozenge to dissolve in the mouth
was previously investigated and found to be 6.77 ±
2.01 min [17].
Both of the AMC/DCBA throat lozenge variants
induced throat numbness from 1 minute post dose and
were significantly different from the unflavoured, non-
medicated lozenge for the duration of 2 hours, as indi-
cated by the AUC data. This can be explained by the
findings of the study by Buchholz et al. [11] where the
two active ingredients of AMC/DCBA throat lozenges,
Table 3 AUC data - ITT set for (A) sore throat relief (TOTPAR) from baseline to 2 hours post dose, (B) change from
baseline in difficulty swallowing from baseline to 2 hours post dose and (C) throat numbness measurements from 1 to
120 minutes post dose
AMC/DCBA
Warm lozenge
AMC/DCBA
Cool lozenge
Unflavoured,
non-medicated
lozenge
(A) Sore throat relief (TOTPAR)
N 77 74 74
Mean ± SD 1.70 ± 1.19 2.06 ± 1.30 0.94 ± 1.04
LS mean
a 1.74 2.10 0.98
Parameter estimates LS mean
b 95% CI P-value
AMC/DCBA Warm lozenge - unflavoured, nonmedicated lozenge 0.76 0.38,1.14 0.0001***
AMC/DCBA Cool lozenge - unflavoured, nonmedicated lozenge 1.12 0.73,1.50 <0.0001***
(B) Difficulty in swallowing
N 77 74 74
Mean ± SD -13.4 ± 14.4 -19.2 ± 14.6 -7.7 ± 13.2
LS mean
c -13.5 -19.3 -7.5
Parameter estimates LS mean
d 95% CI P-value
AMC/DCBA Warm lozenge - unflavoured, non-medicated lozenge -5.9 -10.4,-1.5 0.009***
AMC/DCBA Cool lozenge - unflavoured, non-medicated lozenge -11.7 -16.2,-7.2 <0.0001***
(C) Throat numbness
N 77 74 74
Mean ± SD 1.86 ± 0.83 2.18 ± 0.86 1.54 ± 0.72
LS mean
a 1.80 2.12 1.48
Parameter estimates LS mean
b 95% CI P-value
AMC/DCBA Warm lozenge - unflavoured, non-medicated lozenge 0.32 0.06,0.58 0.017*
AMC/DCBA Cool lozenge - unflavoured, non-medicated lozenge 0.64 0.38,0.90 <0.0001***
aEstimated from ANCOVA model with factors for treatment and centre and a covariate for baseline throat soreness.
bA positive difference favours the first treatment against second treatment.
cEstimated from ANCOVA model with factors for treatment and centre and covariates for baseline throat soreness and baseline score for difficulty in swallowing.
dA negative difference favours the first treatment against second treatment.
***Significantly different compared with the unflavoured, non-medicated lozenge at the 0.1% level.
CI, confidence interval; LS, least-squares; SD, standard deviation.
Sore throat relief measured on a 7-point scale where 0 = No relief, 1 = Slight relief, 2 = Mild relief, 3 = Moderate relief, 4 = Considerable relief, 5 = Almost complete
relief, 6 = Complete relief.
Difficulty in swallowing measured on 100 mm VAS where 0 mm = Not difficult, 100 mm = Very difficult.
Throat numbness measured on a 5-point scale where 1 = None, 2 = Mild, 3 = Moderate, 4 = Considerable, 5 = Complete.
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Page 9 of 14Figure 4 Mean change from baseline in difficulty swallowing from 1 to 120 minutes post dose - ITT set.
Figure 5 Mean throat numbness from 1 to 120 minutes post-dose - ITT set.
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Page 10 of 14AMC and DCBA, were found to act in a local anaes-
thetic-like manner by blocking voltage-gated neuronal
sodium channels in a similar way to lidocaine [11]. The
peak effects observed in this single dose study for pain
relief, throat soreness, difficulty in swallowing and
throat numbness were achieved by 15 and 30 minutes
for the AMC/DCBA Cool and AMC/DCBA Warm
lozenge after initial dosing and lasted for up to 2 hours,
suggesting that the relief provided by both AMC/DCBA
throat lozenge variants is not confined to the time the
throat lozenge remains in the mouth, and that relief is
felt long after the throat lozenge has dissolved. Signifi-
cant analgesic and functional effects on severity of
throat soreness, sore throat relief and difficulty in swal-
lowing have previously been demonstrated with the ori-
ginal AMC/DCBA throat lozenge (which contains only
Table 4 Change from pre-dose to 2 hours post dose in the functional impairment scale (each component and overall
total score) - ITT set
AMC/DCBA
Warm lozenge
AMC/DCBA
Cool lozenge
Unflavoured,
non-medicated
lozenge
Talking
N 77 73 74
Mean ± SD -1.09 ± 2.10 -0.56 ± 2.06 -0.20 ± 2.04
LS mean
a -1.49 -0.99 -0.53
Parameter estimates LS mean
b 95% CI P-value
AMC/DCBA Warm lozenge - unflavoured, nonmedicated lozenges -0.96 -1.59,-0.33 0.003**
AMC/DCBA Cool lozenge - unflavoured, nonmedicated lozenges -0.46 -1.10,0.18 0.15
Swallowing
N 77 73 74
Mean ± SD -1.35 ± 1.89 -1.36 ± 2.07 -0.65 ± 1.86
LS mean
a -1.51 -1.57 -0.80
Parameter estimates LS mean
b 95% CI P-value
AMC/DCBA Warm lozenge - unflavoured, nonmedicated lozenges -0.71 -1.30,-0.13 0.018*
AMC/DCBA Cool lozenge - unflavoured, nonmedicated lozenges -0.77 -1.36,-0.17 0.011*
Concentrating
N 77 73 74
Mean ± SD -0.57 ± 1.82 -0.70 ± 1.83 -0.43 ± 1.28
LS mean
a -0.86 -0.82 -0.63
Parameter estimates LS mean
b 95% CI P-value
AMC/DCBA Warm lozenge - unflavoured, nonmedicated lozenges -0.23 -0.71,0.25 0.34
AMC/DCBA Warm lozenge - AMC/DCBA Cool lozenge -0.19 -0.68,0.29 0.44
Reading
N 77 73 74
Mean ± SD -0.21 ± 1.84 -0.41 ± 1.57 -0.22 ± 1.00
LS mean
a -0.41 -0.54 -0.36
Parameter estimates LS mean
b 95% CI P-value
AMC/DCBA Warm lozenge - unflavoured, nonmedicated lozenge -0.05 -0.49,0.39 0.82
AMC/DCBA Cool lozenge - unflavoured, nonmedicated lozenge -0.18 -0.63,0.27 0.43
TOTAL OF ALL FOUR RESPONSES
N 77 73 74
Mean ± SD -3.2 ± 6.1 -3.0 ± 5.5 -1.5 ± 4.3
LS mean
a -4.1 -3.8 -2.3
Parameter estimates LS mean
b 95% CI P-value
AMC/DCBA Warm lozenge - unflavoured, nonmedicated lozenge -1.9 -3.6,-0.2 0.03*
AMC/DCBA Cool lozenge - unflavoured, nonmedicated lozenge -1.5 -3.2,0.1 0.07
aEstimated from ANCOVA model with factors for treatment and centre and covariates for baseline throat soreness and baseline score for the relevant variable.
bA negative difference favours the first treatment against second treatment.
* Significantly different compared with the unflavoured, non-medicated lozenge at the 5% level.
CI, confidence interval; LS, least-squares; SD, standard deviation.
Each activity measured on an 11-point scale where 0 = Would not interfere at all, 10 = Would completely interfere.
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medicated lozenge, the benefits of which were rapid in
onset and ongoing, lasting long after the lozenge had
gone [15].
Unsurprisingly, for patients with a sore throat the two
functional areas that were considered to be most
impaired at baseline were swallowing and talking, which
support what is currently known [15]. Moreover, the
analgesic benefits reported by the patients translated
into functional benefits, with differences in favour of the
AMC/DCBA Cool and AMC/DCBA Warm lozenge for
swallowing, and in the case of the AMC/DCBA Warm
lozenge, for talking also, compared with the unfla-
voured, non-medicated lozenge. In addition, patients
taking either one of the AMC/DCBA throat lozenge var-
iants reported experiencing soreness relief, relief from
burning, soothing relief, warming relief and pain relief
from the moment they took the throat lozenge, support-
ing the instant effects of these lozenges.
The consumer questionnaire also qualified the sensor-
ial benefits associated with each of the variants over and
above the efficacy benefits observed, i.e. AMC/DCBA
Warm lozenge was associated with a comforting, warm-
ing sensation and AMC/DCBA Cool lozenge was asso-
ciated with a cooling sensation. These sensorial effects
were felt instantly as soon as the lozenge was sucked
and in the case of the AMC/DCBA Cool lozenge, the
cooling sensation lasted for up to 2 hours.
Furthermore, when asked at 2 hours, patients who
took either one of the AMC/DCBA throat lozenge
variants reported feeling better, less distracted, less fru-
strated and happier than before they took the lozenge -
all of which are emotional benefits. Thus, the results of
t h i ss t u d ys u g g e s tt h a tt h ep a t i e n t sw e r ea b l et of e e l
more like themselves and continue with their everyday
lives after taking either of the two AMC/DCBA throat
lozenge variants. It is not unexpected that patients tak-
ing these lozenges would experience both emotional and
physical benefits of pain relief as demonstrated in this
study because if patients are feeling less pain, they are
more likely to be feeling better. As previously demon-
strated, sore throat and ‘sickness’ are highly correlated
Figure 6 Proportion of patients who said they felt less distracted, less frustrated and happier after taking their pre-assigned throat
lozenge.
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enced by the patient is associated with a greater feeling
of sickness/unwellness, and vice versa [3].
Other analgesic studies have concluded that a reduc-
tion of 1-2 points on an 11-point ordinal scale repre-
sented clinically important differences [18-21]. The
magnitude of the changes observed in the present study
both in terms of changes from baseline of each of the
efficacy endpoints, and between each of the AMC/
DCBA throat lozenge variants compared with the unfla-
voured, non-medicated lozenge are therefore clinically
meaningful. These clinically meaningful observations are
in keeping with those reported for the original AMC/
DCBA throat lozenge [15]. Also in keeping with pre-
viously published data is the ‘placebo effect’ observed
with the unflavoured, non-medicated lozenge [15]. How-
ever, this study only investigated the effects of the two
AMC/DCBA throat lozenge variants as a whole in
patients with sore throat, and did not investigate the
sensory impact of the excipients of the two lozenge for-
mulation variants on the placebo effect, which warrants
further investigation.
Similar to the findings from two surveys in healthy
volunteers, the sensorial benefits of a cooling sensation
and a warming sensation experienced by healthy adults
who took a AMC/DCBA Cool or a AMC/DCBA Warm
lozenge, respectively, were mirrored in patients with
acute sore throat, and furthermore, were translated into
both analgesic and functional benefits (Personal Com-
munications) [16].
Conclusions
In conclusion, AMC/DCBA Warm lozenges and AMC/
DCBA Cool lozenges are well-tolerated and effective
OTC treatment options, offering not only functional,
but also instant sensorial as well as emotional benefits
to patients with acute sore throat, over and above that
of the rapid clinically meaningful improvements in effi-
cacy that ensued.
Acknowledgements
The authors would like to thank Quyen Chu, PhD (a member of the
European Medical Writers Association) who provided medical writing and
editorial services on behalf of Reckitt Benckiser Healthcare International.
Author details
1CPS Research, Glasgow, UK.
2Reckitt Benckiser Healthcare International, Hull,
UK.
3Worldwide Clinical Trials, Nottingham, UK.
Authors’ contributions
AGW was involved in the design of the study, the recruitment and
management of the patients, the interpretation of the results and detailed
review of the manuscript. GMC was involved in the study design, co-
ordinated recruitment and management of patients and reviewed the
manuscript. CM and AS were involved in the study design, interpretation of
results and review of the manuscript. MG was the contract statistician
involved in the statistical/data analyses of this study. All authors have read,
reviewed and approved the manuscript.
Competing interests
AGW and GMC are directors of CPS Research who have received research
grants from Reckitt Benckiser Healthcare International for the conduct of this
and previous research.
CM and AS are employees of Reckitt Benckiser Healthcare International, who
are the manufacturers of Strepsils. MAG is a Senior Statisician at Worldwide
Clinical Trials, contracted by Reckitt Benckiser Healthcare International for this
research. This study was funded by Reckitt Benckiser Healthcare
International, UK.
Received: 26 May 2010 Accepted: 18 February 2011
Published: 18 February 2011
References
1. Eccles R: Mechanisms of symptoms of the common cold and influenza.
Br J Hosp Med (Lond) 2007, 68:71-75.
2. Capuron L, Miller AH: Cytokines and psychopathology: lessons from
interferon-alpha. Biol Psychiatry 2004, 56:819-824.
3. Lindbaek M, Francis N, Cannings-John R, Butler CC, Hjortdahl P: Clinical
course of suspected viral sore throat in young adults: cohort study.
Scand J Prim Health Care 2006, 24:93-97.
4. Summers A: Sore throats. Accid Emerg Nurs 2005, 13:15-17.
5. Worrall GJ: Acute sore throat. Can Fam Physician 2007, 53:1961-1962.
6. Del Mar CB, Glasziou PP, Spinks AB: Antibiotics for sore throat. Cochrane
Database Syst Rev 2006, 18:CD000023.
7. UK NICE guidelines on: ’Respiratory tract infections - antibiotic
prescribing: Prescribing of antibiotics for self-limiting respiratory tract
infections in adults and children in primary care’. 2008 [http://www.nice.
org.uk/nicemedia/pdf/CG69FullGuideline.pdf].
8. Richards RME, Cowie G, McCague GJ: In vivo investigations of the
antibacterial activity of lozenges and mouthwashes on the
aerobic bacterial flora of the mouth and throat. Pharm J 1989,
658-663.
9. Richards RME, Xing DKL: In vitro evaluation of the antimicrobial activities
of selected lozenges. J Pharm Sci 1993, 82:1218-1220.
10. Oxford JS, Lambkin R, Gibb I, Balasingam S, Chan C, Catchpole A: A throat
lozenge containing amylmetacresol and dichlorobenzyl alcohol has a
direct virucidal effect on respiratory syncytial virus, influenza A and
SARs-CoV. Antivir Chem Chemother 2005, 16:129-134.
11. Buchholz V, Leuwer M, Ahrens J, Foadi N, Krampfl K, Haeseler G: Topical
antiseptics for the treatment of sore throat block voltage-gated
neuronal sodium channels in a local anaesthetic-like manner. Naunyn
Schmiedebergs Archiv Pharmacol 2009, 380:161-168.
12. Berry P: Rapid relief of acute sore throat with Strepsils lozenges: a single-
blind, comparative study. London: Royal Society of Medicine Press; 2008,
ISBN: 978-1-85315-869-8.
13. Marazzi PJ: Strepsils anaesthetic lozenges versus control Strepsils
lozenges in the relief of moderate-to-severe sore throat: a double-blind,
crossover, multiple-dose, randomized study. London: Royal Society of
Medicine Press; 2008, ISBN: 978-1-85315-869-8.
14. Wade AG: A randomised, double-blind, parallel-group, placebo-
controlled, multiple-dose study of the efficacy of Strepsils lozenges in
the relief of acute sore throat. London: Royal Society of Medicine Press;
2008, ISBN: 978-1-85315-869-8.
15. McNally D, Saddiq M, Simpson M, Holbrook A, Shephard A, Goulder M:
Rapid relief of acute sore throat with AMC/DCBA throat lozenges:
randomised controlled trial. Int J Clin Pract 2010, 64:194-207.
16. Shephard A, Aspley S, Sykes J, Parkin T: Strepsils Cool lozenges provide an
instant cooling effect: consumer research study in healthy volunteers.
London: Royal Society of Medicine Press; 2008, ISBN: 978-1-85315-869-8.
17. Wade AG, Marshall LE, Simpson M, Shephard A: Bioavailability and efficacy
of active lozenges in the relief of sore throat pain. Poster presented at
the Annual Scientific Meeting of the British Pain Society. Glasgow, UK; 2007.
18. Interactive Textbook on Clinical Symptom Research: Chapter 1: The
Design of Clinical Trials for Treatment of Pain.Edited by: Mitchell B.
Max, MD, National Institute of Dental and Craniofacial Research, NIH;
[http://symptomresearch.nih.gov].
Wade et al. BMC Family Practice 2011, 12:6
http://www.biomedcentral.com/1471-2296/12/6
Page 13 of 1419. Salaffi F, Stancati A, Silvestri CA, Ciapetti A, Grassi W: Minimum clinically
important changes in chronic musculoskeletal pain intensity measured
on a numerical rating scale. Eur J Pain 2004, 8:283-291.
20. Farrar JT, Young JP, LaMoreaux L, Werth JL, Poole M: Clinical importance of
changes in chronic pain intensity measured on an 11-point numerical
pain rating scale. Pain 2001, 94:149-158.
21. Farrar JT, Berlin JA, Strom BL: Clinically important changes in acute pain
outcome measures: a validation study. J Pain Sympt Man 2003,
25:406-411.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2296/12/6/prepub
doi:10.1186/1471-2296-12-6
Cite this article as: Wade et al.: A multicentre, randomised, double-
blind, single-dose study assessing the efficacy of AMC/DCBA Warm
lozenge or AMC/DCBA Cool lozenge in the relief of acute sore throat.
BMC Family Practice 2011 12:6.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Wade et al. BMC Family Practice 2011, 12:6
http://www.biomedcentral.com/1471-2296/12/6
Page 14 of 14